Atria Investments LLC boosted its holdings in shares of Novartis AG (NYSE:NVS) by 10.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 24,404 shares of the company’s stock after buying an additional 2,349 shares during the quarter. Atria Investments LLC’s holdings in Novartis were worth $2,049,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also made changes to their positions in NVS. Parnassus Investments CA boosted its position in shares of Novartis by 18.5% in the third quarter. Parnassus Investments CA now owns 9,447,817 shares of the company’s stock worth $811,095,000 after purchasing an additional 1,477,168 shares during the period. Fisher Asset Management LLC boosted its position in shares of Novartis by 2.0% in the third quarter. Fisher Asset Management LLC now owns 6,632,984 shares of the company’s stock worth $569,442,000 after purchasing an additional 127,049 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Novartis by 3.1% in the second quarter. The Manufacturers Life Insurance Company now owns 5,036,427 shares of the company’s stock worth $420,390,000 after purchasing an additional 151,115 shares during the period. BlackRock Inc. boosted its position in shares of Novartis by 25.3% in the second quarter. BlackRock Inc. now owns 3,549,783 shares of the company’s stock worth $296,299,000 after purchasing an additional 717,186 shares during the period. Finally, State Street Corp boosted its position in shares of Novartis by 2.3% in the second quarter. State Street Corp now owns 3,046,276 shares of the company’s stock worth $254,273,000 after purchasing an additional 68,834 shares during the period. Institutional investors own 10.85% of the company’s stock.
Novartis AG (NYSE NVS) opened at $86.41 on Friday. Novartis AG has a 1-year low of $69.53 and a 1-year high of $87.29. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.08 and a quick ratio of 0.81. The company has a market cap of $225,820.00, a price-to-earnings ratio of 30.75, a PEG ratio of 2.32 and a beta of 0.74.
Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.25 by $0.04. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The firm had revenue of $12.41 billion for the quarter, compared to the consensus estimate of $12.21 billion. During the same quarter in the previous year, the firm earned $1.23 earnings per share. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. research analysts expect that Novartis AG will post 4.79 EPS for the current fiscal year.
A number of research firms have weighed in on NVS. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a research report on Thursday. UBS Group reiterated a “neutral” rating on shares of Novartis in a research report on Monday. Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Nord/LB reiterated a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Finally, Bank of America lowered shares of Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th. Five analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the stock. Novartis has a consensus rating of “Hold” and a consensus price target of $85.32.
TRADEMARK VIOLATION NOTICE: “Atria Investments LLC Acquires 2,349 Shares of Novartis AG (NVS)” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://transcriptdaily.com/2018/01/19/atria-investments-llc-acquires-2349-shares-of-novartis-ag-nvs.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.